// App-Quantinova.ai

: High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial

Researchers

Presenter

  • Chong Chyn Chua

Principal Investigators

  • Sun Loo

  • John Reynolds

  • Ing S Tiong

  • Chun Yew Fong

  • Stephen B Ting

  • Shaun Fleming

  • Andrew W Roberts

  • Andrew H Wei

Medical Centers

  • Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia

  • Department of Haematology, The Alfred Hospital and Monash University, Melbourne, Australia

  • Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, Australia

  • The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

  • The Alfred Hospital and Monash University, Melbourne, Australia

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Cytochrome P450 Family 3 Subfamily A Member 4

Drug/Treatment

  • Cytarabine liposomal

  • Idarubicin Hydrochloride

  • Venetoclax

Outcome

  • N/A

Study Design

  • Safety

  • Dose Escalation

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved